Literature DB >> 21741874

Parkinson's disease: the non-motor issues.

K Ray Chaudhuri1, Per Odin, Angelo Antonini, Pablo Martinez-Martin.   

Abstract

Non-motor symptoms (NMS) of Parkinson's disease remain the most under-appreciated and under-researched when taken as a whole. Data is emerging that it is the "totaL" burden of NMS that is the major determinant of quality of life not a single NMS such as depression for instance. Only recently validated tools such as the NMSQuest which empowers patients to declare NMS and the NMS scale, the SCOPA scales, and the modified version of the MDS-UPDRS have become available and validated for bedside clinical assessment of NMS. For the first time clinical trials have been incorporating non-motor measures as outcome measures and clinical recommendations for treatment of non-motor symptoms of PD are being published. This review aims to address some of these topical and "real life" aspects of modern day management of Parkinson's.
Copyright © 2011. Published by Elsevier Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21741874     DOI: 10.1016/j.parkreldis.2011.02.018

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  96 in total

1.  Proceedings: cell therapies for Parkinson's disease from discovery to clinic.

Authors:  Rosa Canet-Aviles; Geoffrey P Lomax; Ellen G Feigal; Catherine Priest
Journal:  Stem Cells Transl Med       Date:  2014-08-22       Impact factor: 6.940

2.  Psychometric properties of the Italian version of the Scales for Outcomes in Parkinson's disease- Cognition (SCOPA-Cog).

Authors:  V Isella; C Mapelli; N Morielli; D De Gaspari; C Siri; G Pezzoli; A Antonini; M Poletti; U Bonuccelli; L Picchi; A Napolitano; M Vista; M Veglia; F Piamarta; F Grassi; I M Appollonio
Journal:  Funct Neurol       Date:  2013 Apr-May

3.  Chronic nicotine improves cognitive and social impairment in mice overexpressing wild type α-synuclein.

Authors:  Sudhakar R Subramaniam; Iddo Magen; Nicholas Bove; Chunni Zhu; Vincent Lemesre; Garima Dutta; Chris Jean Elias; Henry A Lester; Marie-Francoise Chesselet
Journal:  Neurobiol Dis       Date:  2018-06-01       Impact factor: 5.996

4.  Cross-cultural adaptation and psychometric properties of the SCOPA-Sleep-German version.

Authors:  Simone Goebel; Elisabeth Steinmann; Bernd Leplow; H Maximilian Mehdorn
Journal:  Neurol Sci       Date:  2018-04-14       Impact factor: 3.307

Review 5.  Parkinson's disease in Nigeria: A review of published studies and recommendations for future research.

Authors:  Oluwafemi G Oluwole; Helena Kuivaniemi; Jonathan A Carr; Owen A Ross; Matthew O B Olaogun; Soraya Bardien; Morenikeji A Komolafe
Journal:  Parkinsonism Relat Disord       Date:  2018-12-08       Impact factor: 4.891

6.  The prevalence of chronic low back pain and lumbar deformities in patients with Parkinson's disease: implications on spinal surgery.

Authors:  Imke Galazky; Christina Caspari; Hans-Jochen Heinze; Joerg Franke
Journal:  Eur Spine J       Date:  2018-09-08       Impact factor: 3.134

Review 7.  Sensory aspects of movement disorders.

Authors:  Neepa Patel; Joseph Jankovic; Mark Hallett
Journal:  Lancet Neurol       Date:  2014-01       Impact factor: 44.182

Review 8.  An update on the use of botulinum toxin therapy in Parkinson's disease.

Authors:  Reversa Mills; Laxman Bahroo; Fernando Pagan
Journal:  Curr Neurol Neurosci Rep       Date:  2015-01       Impact factor: 5.081

9.  Imaging changes associated with cognitive abnormalities in Parkinson's disease.

Authors:  Yuko Koshimori; Barbara Segura; Leigh Christopher; Nancy Lobaugh; Sarah Duff-Canning; Romina Mizrahi; Clement Hamani; Anthony E Lang; Kelly Aminian; Sylvain Houle; Antonio P Strafella
Journal:  Brain Struct Funct       Date:  2014-05-13       Impact factor: 3.270

10.  Cognitive function and other non-motor features in non-demented Parkinson's disease motor subtypes.

Authors:  Talia Herman; Aner Weiss; Marina Brozgol; Adi Wilf-Yarkoni; Nir Giladi; Jeffrey M Hausdorff
Journal:  J Neural Transm (Vienna)       Date:  2014-12-10       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.